VX-864 + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha1-Antitrypsin Deficiency
Conditions
Alpha1-Antitrypsin Deficiency
Trial Timeline
Jul 24, 2020 → May 4, 2021
NCT ID
NCT04474197About VX-864 + Placebo
VX-864 + Placebo is a phase 2 stage product being developed by Vertex Pharmaceuticals for Alpha1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT04474197. Target conditions include Alpha1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04474197 | Phase 2 | Completed |
Competing Products
3 competing products in Alpha1-Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) | Grifols | Phase 1/2 | 29 |
| Alpha-1 MP | Grifols | Phase 1/2 | 29 |
| Alpha-1 MP | Grifols | Phase 1/2 | 29 |